Skip to main content

Table 4 Mean survival based on CTC positivity, TIMP-1 and CAIX levels

From: Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer

 

PFS in months

Pvalue

OS in months

Pvalue

CTC negative

 

< 0.011

 

< 0.011

TIMP-1

    

   Non elevated

12.3(10.6-14.1)

< 0.012

21.4 (20.3-22.6)

< 0.01

   Elevated

4.4 (2.8-6.0)

 

12.0 (8.2-15.7)

 

CTC positive

    

TIMP-1

    

   Non elevated

9.5 (7.6-11.4)

0.81

15.5 (13.3-17.7)

0.151

   Elevated

8.5 (6.2-10.8)

 

12.0 (9.4-14.6)

 

CTC negative

 

< 0.011

 

< 0.011

CAIX

    

   Non elevated

11.6 (9.8-13.5)

0.06

21.3 (20.0-22.6)

< 0.01

   Elevated

8.1 (5.6-10.6)

 

15.9 (12.8-19.0)

 

CTC positive

    

CAIX

    

   Non elevated

11.0(8.7-13.1)

< 0.05

16.2 (14.0-18.4)

< 0.05

   Elevated

7.1(5.2-9.0)

 

11.8 (9.5-14.1)

 
  1. 1P value for comparing differences between all four groups, 2comparing survival differences for comparing marker positivity within CTC negative and positive patients
  2. CAIX, carbonic anhydrase IX; CTC, circulating tumor cell; OS, overall survival; PFS, progression-free survival; TIMP, tissue inhibitor of metalloproteinase.